Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Cell Death & Disease|April 6, 2026
The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancerJ Searle, M Menotti, W J McDaid, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.
Lung Cancer (Amsterdam, Netherlands)|April 25, 2006
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapyF Cappuzzo, S Novello, F De Marinis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1996
Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant diseaseE Bajetta, A Di Leo, L Biganzoli, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2000
p53 and related proteins in epithelial ovarian cancerP S Sengupta, A T McGown, V Bajaj, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2019
Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trialR Y Tay, F Fernández-Gutiérrez, V Foy, et al.
Lung Cancer (Amsterdam, Netherlands)|May 30, 2023
KRAS G12C mutation and risk of disease recurrence in stage I surgically resected lung adenocarcinomaF T Gallina, D Marinelli, E Melis, et al.
British Journal of Cancer|January 26, 2013
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patientsV Martin, L Landi, F Molinari, et al.
British Journal of Cancer|June 16, 2005
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancerF Cappuzzo, S Novello, F De Marinis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 25, 2010
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trialsP Wheatley-Price, F Blackhall, S-M Lee, et al.
Pageof 9